In people with type 2 diabetes, a medication called tirzepatide at doses of 5 mg or higher raises levels of certain blood proteins—adiponectin, IGFBP-1, and IGFBP-2—more than another medication...
Mechanism
Synthesis from 1 study
Tirzepatide works better than dulaglutide because it hits two different receptors in fat and liver cells, making those cells release more proteins that help insulin work better. This happens even without weight loss, which is why it’s more effective at improving how the body handles sugar.
Most probable mechanism
Tirzepatide activates two specific receptors on fat cells and liver cells, which causes the fat cells to release more of a protein called adiponectin and the liver to release more of two other proteins called IGFBP-1 and IGFBP-2. These proteins help the body use insulin more effectively, allowing blood sugar to be taken up by muscles and fat without needing as much insulin.
Tirzepatide binds to GIP receptors on adipocytes and GLP-1 receptors on pancreatic beta cells and hepatocytes
GIP receptor activation on adipocytes stimulates synthesis and secretion of adiponectin
Tirzepatide activates signaling pathways in hepatocytes that upregulate production and release of IGFBP-1 and IGFBP-2
Increased adiponectin enhances glucose uptake in adipose and muscle tissue via GLUT4 translocation
Elevated IGFBP-1 and IGFBP-2 reduce free IGF-1 bioavailability and enhance insulin signaling in liver and skeletal muscle
These changes collectively reduce insulin resistance in liver and peripheral tissues independently of weight loss
Less supported by current evidence, but not ruled out
Tirzepatide reduces the amount of glucagon released by the pancreas, which tells the liver to stop making too much sugar. This lowers blood sugar levels and makes insulin work better, even if the body hasn't lost weight.
Tirzepatide activates GLP-1 and GIP receptors on pancreatic alpha cells
Receptor activation inhibits glucagon secretion via cAMP-dependent signaling
Reduced glucagon signaling decreases hepatic gluconeogenesis and glycogenolysis
Lower hepatic glucose production reduces fasting hyperglycemia and improves systemic insulin sensitivity
Evidence from Studies
Supporting (1)
Community contributions welcome
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.